Atibuclimab

Phase 1Monoclonal antibody

IImplicit Bioscience

Atibuclimab is one of 50 biologic programs targeting Heart Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

OsteoarthritisActive, not recruiting

Heart FailurePhase 1/Phase 2

Active, not recruiting

OsteoarthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 3

Bayer Aspirin

Platelet Rich Plasma

25 5

Enbrel

IImmunex

Preclinical

2 6

Glucophage

Boehringer Ingelheim

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Botox

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Pilot Study

NCT06678074

Q4 2027

Phase 2Recruiting

Treatment

NCT06513949

Q1 2028

Phase 1Not yet recruiting

Osteoarthritis

NCT07481474

Clinical

Trials by Indication[1]

Treatment1 trial

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Recruiting·IImplicit Bioscience·Phase 2·NCT06513949·56 enrolled

Pilot Study1 trial

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Recruiting·IImplicit Bioscience·Phase 1/2·NCT06678074·10 enrolled

Heart Failure1 trial

IC14 for Treatment of Acute Decompensated Heart Failure

Active, not recruiting·IImplicit Bioscience·Phase 1/2·NCT06556810·10 enrolled

Osteoarthritis1 trial

Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee Osteoarthritis

Not yet recruiting·VVA Office of Research and Development·Phase 1·NCT07481474·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Atibuclimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atibuclimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atibuclimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Implicit Bioscience company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: IImplicit Bioscience

Atibuclimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Q1 2028

Trials by Indication[1]

Treatment1 trial

Pilot Study1 trial

Heart Failure1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News